drugset
drugset / Trial / NCT02607553

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

NCT02607553 ↗

Phase 2 Completed 2 enrolled GenSpera, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm, single-center Phase II study to evaluate the safety and activity of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA

Timeline

Start
2016-06
Primary completion
2016-12
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mipsagargin Other / unclassified — Intravenous

Indications

clear cell renal carcinoma